Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis

BACKGROUND: Trastuzumab emtansine (T-DM1) is an anti-HER2 antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer. One of the most severe adverse events reported with T-DM1 is hepatotoxicity. The objective of our meta-analysis is to investigate the risk of hepatic adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Cobert, Amani M., Helms, Catherine, Larck, Chris, Moore, Donald C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175051/
https://www.ncbi.nlm.nih.gov/pubmed/32341779
http://dx.doi.org/10.1177/2042098620915058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175051/
https://www.ncbi.nlm.nih.gov/pubmed/32341779
http://dx.doi.org/10.1177/2042098620915058

Ejemplares similares